Market Size, Share, Growth, Opportunities, and Forecast for the U.S. intravenous immunoglobulin market, 2021-2028

 

The market for intravenous immunoglobulin is expanding as a result of a considerable increase in the elderly population and the number of hemophiliac patients, as well as new technologies for producing immunoglobulin and improved purifying methods (with better plasma yield). Additionally, an increase in the prevalence of disorders including hypogammaglobulinemia and chronic inflammatory demyelinating polyneuropathy (CIDP) is anticipated to spur market expansion. However, the use of intravenous immunoglobulin products is subject to strict government rules, and there is a substantial danger that they will have unfavorable side effects. Contrarily, it is anticipated that in the near future, the widespread use of the U.S. Intravenous Immunoglobulin Market for the treatment of numerous diseases would lead to prosperous chances.

U.S. Intravenous Immunoglobulin Market, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others are segments of the global intravenous immunoglobulin market. The U.S. Intravenous Immunoglobulin Market's largest contributor in 2017 was the hypogammaglobulinemia sector, and it is projected that it will continue to dominate for the duration of the forecast. This is explained by the considerable global increase in the prevalence of hypogammaglobulinemia disease throughout time. For instance, the most prevalent chronic immunological deficiency in people with lymphoproliferative diseases is hypogammaglobulinemia (LPDs). 

The U.S. Intravenous Immunoglobulin Market is anticipated to rise as a result of the rising number of research and development activities. For example, on August 25, 2021, Emergent BioSolutions Inc., a multinational specialty biopharmaceutical company with headquarters in the U.S., announced the beginning of a Phase III clinical trial to assess the potential efficacy of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy as an outpatient treatment for patients with coronavirus (COVID-19) who are at high risk

Competitive Environment of the U.S. Intravenous Immunoglobulin Market

Biotest AG, Octapharma AG, Grifols S.A., Kedrion Biopharma, Inc., CSL Behring, McKesson Corporation, Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Pfizer, Inc., and ADMA Biologics, Inc. are significant market participants in the U.S. intravenous immunoglobulin industry.